Skip to main content

Table 1 Drug resistance-related genes differentially expressed after MenSC coculture via epigenetic alterations

From: Genome-wide DNA methylation and hydroxymethylation analysis reveal human menstrual blood-derived stem cells inhibit hepatocellular carcinoma growth through oncogenic pathway suppression via regulating 5-hmC in enhancer elements

Genes Expression after MenSC therapy Epigenetic alteration after MenSC therapy Expression in literature Drug resistance
ID4 Downregulated 5mC upregulation in the promoter
5-hmC downregulation in the enhancer
Upregulated Glioma: 1,3-bis(2-chloroethyl)-1-nitrosourea
SQSTM1 Downregulated 5-hmC downregulation in the promoter Upregulated Ovarian cancer: cisplatin
Gastric cancer: cisplatin
HMGA1 Downregulated 5mC upregulation in the enhancer
5-hmC downregulation in the enhancer
Upregulated Lung cancer: tyrosine kinase inhibitor
Ovarian cancer: paclitaxel, doxorubicin
Sarcoma: trabectedin
Cholangiocarcinoma: gemcitabine
GATA2 Downregulated 5-mC upregulation in the enhancer
5-hmC downregulation in the enhancer
Upregulated Prostate cancer: docetaxel, cabazitaxel
PSAT1 Downregulated 5-hmC downregulation in the enhancer Upregulated Colorectal cancer: oxaliplatin
Breast cancer: tamoxifen
FASN Downregulated 5-hmC downregulation in the enhancer Upregulated Ovarian cancer: cisplatin
Lung cancer: tyrosine kinase inhibitor
Gastrointestinal stromal tumor: imatinib
Triple-negative breast cancer: cetuximab